07Nov 2026
Weight Loss Does Not Explain Cardiovascular Benefits of Incretin Therapies, Meta-Analysis Finds

Weight Loss Does Not Explain Cardiovascular Benefits of Incretin Therapies, Meta-Analysis Finds

A meta-analysis of 16 randomised trials involving 97,199 participants found that incretin mimetic therapies significantly reduced major cardiovascular events, cardiovascular and all-cause mortality, myocardial infarction, stroke and heart failure hospitalisation. However, trial-level weight loss was not significantly associated with the magnitude of cardiovascular risk reduction, suggesting that weight loss alone may not explain these benefits.

  • #endo-diabetology

Like

Save

Share